Laminin 111 E8

Produktanfrage

Laminin 111 E8 Molekülhintergrund

Laminin 111 is an extracellular matrix protein that has also been promoted for its ability to improve muscle regeneration and stabilize the plasma membrane in multiple forms of muscular dystrophy. Laminin 111 E8 is composed of the C-terminal end of Laminin alpha1, beta 1 and gamma 1 chains.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
KN-057	KN-057; KN057	Phase 3 Clinical	Suzhou Alphamab Co Ltd	Hemophilia A; Hemophilia B	Details
MG-1113	MG-1113	Phase 1 Clinical	GC Biopharma Corp	Hemophilia A	Details
AP-017	AP017; AP-017	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hemophilia A; Hemophilia B	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Concizumab	mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021	Approved	Novo Nordisk A/S	Alhemo	Canada	Hemophilia B	Novo Nordisk Canada Inc	2023-04-17	Hemophilia A; Hemophilia B; Hemorrhage	Details
Marstacimab	PF-6741086; PF-06741086	Approved	Pfizer Inc	HYMPAVZI	United States	Hemophilia A; Hemophilia B	Pfizer Inc	2024-10-11	Hemophilia A; Hemophilia B; Hemorrhage	Details